Germline BRCA-mutated metastatic breast cancer with positive hormone receptor

Affiliations

¹ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, 47014, Meldola, Italy.
² Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, 47014, Meldola, Italy. chiara.casadei@irst.emr.it.

Comment

Michela Palleschi et al. Breast Cancer Res Treat. 2021 Feb.

. 2021 Feb;186(1):265-266.

doi: 10.1007/s10549-020-06010-9. Epub 2020 Nov 10.

¹ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, 47014, Meldola, Italy.
² Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, 47014, Meldola, Italy. chiara.casadei@irst.emr.it.

No abstract available

Comment on

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B. Domchek SM, et al. Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6. Lancet Oncol. 2020. PMID: 32771088 Clinical Trial.

1. Domchek SM, Postel-Vinay S, Im SA et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21(9):1155–1164. https://doi.org/10.1016/S1470-2045(20)30324-7 - DOI - PubMed
1. Andre F, Su F, Solovieff N et al (2020) Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. J Clin Oncol 38(15_suppl):1009. https://doi.org/10.1200/JCO.2020.38.15_suppl.1009 - DOI
1. Mote PA, Leary JA, Avery KA et al (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosom Cancer 39(3):236–248. https://doi.org/10.1002/gcc.10321 - DOI - PubMed